
Claims

1. A compound of the formula I



(I)

in which

X^1 is -O-, -O-CH_2-, -O-C(=O)-, -NR^{11}-, -NR^{11}-CH_2- or -NR^{11}-C(=O)-;
X^2 is a single bond, CO or CH_2;
X^3 is N or CH;
X^4 is N or CH;
A is phenylene or 6-membered hetarylene with 1 or 2 nitrogen atoms as ring members, where phenylene or hetarylene may be substituted by 1 or 2 radicals R^{10};
R^1 and R^3 are independently of one another hydrogen, C_1-C_3-alkyl, C_1-C_3-fluoroalkyl, C_1-C_3-alkoxy, C_1-C_3-fluoroalkoxy, halogen or CN;
R^2 is hydrogen or methoxy;

where at least one of the radicals R^1, R^2 and R^3 is hydrogen;

R^4 is hydrogen or C_1-C_4-alkyl;
R^5 is ethoxy, fluorinated ethoxy, fluoromethoxy, difluoromethoxy, trifluoromethoxy or isopropoxy;
R^6 is hydrogen or methyl;
R^7 is hydrogen, I, Br, Cl, F or CN;
R^8 is hydrogen, I, Br, Cl, F or CN;
R^9 is C_1-C_3-alkyl or C_1-C_3-fluoroalkyl;

R^{10} is C_1-C_3-alkyl, C_1-C_3-fluoroalkyl, C_1-C_3-alkoxy or C_1-C_3-fluoroalkoxy;
R^{11} is hydrogen, C_1-C_4-alkyl, C_1-C_4-fluoroalkyl, C_1-C_4-alkoxy or C_1-C_4-fluoroalkoxy;
a is 0, 1 or 2; and
m and n are independently of one another 1 or 2;

and their pharmaceutically acceptable salts and prodrugs thereof.

2. A compound as claimed in claim 1, in which R^1 is hydrogen, methoxy, ethoxy, fluoromethoxy, difluoromethoxy or trifluoromethoxy.

3. A compound as claimed in claim 2, in which R^1 is hydrogen, methoxy or trifluoromethoxy.

4. A compound as claimed in claim 3, in which R^1 is hydrogen or methoxy.

5. A compound as claimed in any of the preceding claims, in which R^2 is hydrogen.

6. A compound as claimed in any of the preceding claims, in which R^3 is hydrogen or methoxy.

7. A compound as claimed in any of the preceding claims, in which R^4 is hydrogen, methyl or ethyl.

8. A compound as claimed in any of the preceding claims, in which R^5 is ethoxy or fluorinated ethoxy.

9. A compound as claimed in claim 8, in which R^5 is ethoxy, 2,2-difluoroethoxy or 2,2,2-trifluoroethoxy.

10. A compound as claimed in claim 9, in which R^5 is ethoxy.

11. A compound as claimed in any of the preceding claims, in which R^6 is hydrogen.

12. A compound as claimed in any of the preceding claims, in which R^7 and R^8 are not simultaneously CN.

13. A compound as claimed in any of the preceding claims, in which R^7 is CN and R^8 is H or F.

14. A compound as claimed in any of claims 1 to 12, in which R^7 is I and R^8 is H or F.

15. A compound as claimed in any of claims 1 to 12, in which R^7 is Cl and R^8 is H or F.

16. A compound as claimed in any of the preceding claims, in which R^9 is methyl or ethyl.

17. A compound as claimed in any of the preceding claims, in which R^{10} is methyl or methoxy.

18. A compound as claimed in any of the preceding claims, in which R^{11} is H.

19. A compound as claimed in any of the preceding claims, in which a is 0.

20. A compound as claimed in any of the preceding claims, in which X^1 is -O-C(=O)-, -NH-, -NH-CH_2- or -NH-C(=O)-.

21. A compound as claimed in claim 20, in which X^1 is -NH-CH_2-.

22. A compound as claimed in any of the preceding claims, in which X^2 is a single bond.

23. A compound as claimed in any of the preceding claims, in which X^3 is N, and m and n are both 2.

24. A compound as claimed in any of claims 1 to 22, in which X^3 is CH, and m and n are both 2, or are both 1, or m is 1 and n is 2.

25. A compound as claimed in any of the preceding claims, in which X^4 is N.

26. A compound as claimed in any of the preceding claims, in which A is phenylene.

27. A compound as claimed in claim 26, in which A is 1,4- or 1,3-phenylene.

28. A compound as claimed in any of claims 1 to 25, in which A is pyridylene or pyrimidylene.


29. A compound as claimed in claim 28, in which A is 3,5- or 3,6-pyridylene.

30. A compound as claimed in any of claims 1 to 27, in which
R^1 is H or methoxy;
R^2 is H;

R^3 is methoxy;
R^4 is H, methyl or ethyl;
R^5 is ethoxy;
R^6 is H;
R^7 is CN;
R^8 is H or F;
X^1 is -NH- or -$NHCH_2$-;
X^2 is a single bond;
X^3 is N;
X^4 is N;
A is 1,4-phenylene;
a is 0; and
m and n are 2.

31. A compound as claimed in claim 30, in which
R^1 is H or methoxy;
R^2 is H;
R^3 is methoxy;
R^4 is H or methyl;
R^5 is ethoxy;
R^6 is H;
R^7 is CN;
R^8 is H or F;
X^1 is -$NHCH_2$-;
X^2 is a single bond;
X^3 is N;
X^4 is N;
A is 1,4-phenylene;
a is 0, and
m and n are 2.

32. A compound of the formula XVIII



(XVIII)

in which R^1, R^2, R^3, R^5, R^6, R^7, R^8, X^1, X^4 and A are as defined in any of the preceding claims, and

R^{12} is halogen, CN, OR^a or NR^bR^c, in which

R^a is H, C_1-C_4-alkyl, phenyl or benzyl; and

R^b and R^c are independently of one another H, C_1-C_4-alkyl, C_1-C_4-alkoxy, phenyl or benzyl.

33. A compound as claimed in claim 32, in which R^{12} is halogen.

34. A pharmaceutical composition comprising at least one compound of the formula I as defined in any of claims 1 to 31 and/or at least one pharmaceutically acceptable salt or prodrug thereof and at least one pharmaceutically acceptable carrier.

35. The use of compounds of the formula I as defined in any of claims 1 to 31 or of pharmaceutically acceptable salts or prodrugs thereof for the manufacture of a medicament for the treatment and/or prophylaxis of vasopressin-dependent diseases.

36. The use of compounds of the formula I as defined in any of claims 1 to 31 or of pharmaceutically acceptable salts or prodrugs thereof for the manufacture of a medicament for the treatment and/or prophylaxis of diseases selected from diabetes, insulin resistance, nocturnal enuresis, incontinence and diseases in which impairments of blood clotting occur, and/or for delaying micturition.

37. The use of compounds of the formula I as defined in any of claims 1 to 31 or of pharmaceutically acceptable salts or prodrugs thereof for the manufacture of a medicament for the treatment and/or prophylaxis of diseases selected from hypertension, pulmonary hypertension, heart failure, myocardial infarction, coronary spasm, unstable angina, PTCA (percutaneous transluminal coronary angioplasty), ischemias of the heart, impairments of the renal system, edemas, renal vasospasm, necrosis of the renal cortex, hyponatremia, hypokalemia, Schwartz-Bartter syndrome, impairments of the gastrointestinal tract, gastritic vasospasm, hepatocirrhosis, gastric and intestinal ulcers, emesis, emesis occurring during chemotherapy, and travel sickness.

38. The use of compounds of the formula I as defined in any of claims 1 to 31 or of pharmaceutically acceptable salts or prodrugs thereof for the manufacture of a medicament for the treatment and/or prophylaxis of diseases selected from affective disorders.

39. The use of compounds of the formula I as defined in any of claims 1 to 31 or of pharmaceutically acceptable salts or prodrugs thereof for the manufacture of a medicament for the treatment and/or prophylaxis of diseases selected from anxiety disorders and stress-dependent anxiety disorders.

40. The use of compounds of the formula I as defined in any of claims 1 to 31 or of pharmaceutically acceptable salts or prodrugs thereof for the manufacture of a medicament for the treatment and/or prophylaxis of diseases selected from memory impairments and Alzheimer's disease.

41. The use of compounds of the formula I as defined in any of claims 1 to 31 or of pharmaceutically acceptable salts or prodrugs thereof for the manufacture of a medicament for the treatment and/or prophylaxis of diseases selected from psychoses and psychotic disorders.

42. The use of compounds of the formula I as defined in any of claims 1 to 31 or of pharmaceutically acceptable salts or prodrugs thereof for the manufacture of a medicament for the treatment and/or prophylaxis of diseases selected from Cushing's syndrome and other stress-dependent diseases.

43. The use of compounds of the formula I as defined in any of claims 1 to 31 or of pharmaceutically acceptable salts or prodrugs thereof for the manufacture of a medicament for the treatment and/or prophylaxis of diseases selected from sleep disorders.

44. The use of compounds of the formula I as defined in any of claims 1 to 31 or of pharmaceutically acceptable salts or prodrugs thereof for the manufacture of a medicament for the treatment and/or prophylaxis of diseases selected from depressive disorders.

45. The use as claimed in claim 44 for the treatment and/or prophylaxis of childhood onset mood disorders.

46. The use of compounds of the formula I as defined in any of claims 1 to 31 or of pharmaceutically acceptable salts or prodrugs thereof for the manufacture of a medicament for the treatment and/or prophylaxis of vasomotor symptoms and/or thermoregulatory dysfunctions.


47. The use of compounds of the formula I as defined in any of claims 1 to 31 or of pharmaceutically acceptable salts or prodrugs thereof for the manufacture of a medicament for the treatment and/or prophylaxis of drug or pharmaceutical dependencies and/or dependencies mediated by other factors; of stress caused by withdrawal of one or more factors mediating the dependence; and/or of stress-induced relapses into drug or pharmaceutical dependencies and/or dependencies mediated by other factors.

48. The use of compounds of the formula I as defined in any of claims 1 to 31 or of pharmaceutically acceptable salts or prodrugs thereof for the manufacture of a medicament for the treatment and/or prophylaxis of diseases selected from schizophrenia and psychosis.

49. A method for treating disorders defined as in any of claims 35 to 48, in which an effective amount of at least one compound of the formula I as defined in any of claims 1 to 31 or of at least one pharmaceutically acceptable salt or a prodrug thereof or of a pharmaceutical composition as claimed in claim 34 is administered to a patient.

Claims

1. A compound of the formula I



(I)

in which

X^1 is -O-, -O-CH_2-, -O-C(=O)-, -NR^{11}-, -NR^{11}-CH_2- or -NR^{11}-C(=O)-;

X^2 is a single bond, CO or CH_2;

X^3 is N or CH;

X^4 is N or CH;

A is phenylene or 6-membered hetarylene with 1 or 2 nitrogen atoms as ring members, where phenylene or hetarylene may be substituted by 1 or 2 radicals R^{10};

R^1 and R^3 are independently of one another hydrogen, C_1-C_3-alkyl, C_1-C_3-fluoroalkyl, C_1-C_3-alkoxy, C_1-C_3-fluoroalkoxy, halogen or CN;

R^2 is hydrogen or methoxy;

where at least one of the radicals R^1, R^2 and R^3 is hydrogen;

R^4 is hydrogen or C_1-C_4-alkyl;

R^5 is ethoxy, fluorinated ethoxy, fluoromethoxy, difluoromethoxy, trifluoromethoxy or isopropoxy;

R^6 is hydrogen or methyl;

R^7 is hydrogen, I, Br, Cl, F or CN;

R^8 is hydrogen, I, Br, Cl, F or CN;

R^9 is C_1-C_3-alkyl or C_1-C_3-fluoroalkyl;

R^{10} is C_1-C_3-alkyl, C_1-C_3-fluoroalkyl, C_1-C_3-alkoxy or C_1-C_3-fluoroalkoxy;

R^{11} is hydrogen, C_1-C_4-alkyl, C_1-C_4-fluoroalkyl, C_1-C_4-alkoxy or C_1-C_4-fluoroalkoxy;

a is 0, 1 or 2; and

m and n are independently of one another 1 or 2;

or a pharmaceutically acceptable salt thereof.

2. A compound or pharmaceutically acceptable salt as claimed in claim 1, in which R^1 is hydrogen, methoxy, ethoxy, fluoromethoxy, difluoromethoxy or trifluoromethoxy.

3. A compound or pharmaceutically acceptable salt as claimed in claim 2, in which R^1 is hydrogen, methoxy or trifluoromethoxy.

4. A compound or pharmaceutically acceptable salt as claimed in claim 3, in which R^1 is hydrogen or methoxy.

5. A compound or pharmaceutically acceptable salt as claimed in any one of claims 1 to 4, in which R^2 is hydrogen.

6. A compound or pharmaceutically acceptable salt as claimed in any one of claims 1 to 5, in which R^3 is hydrogen or methoxy.

7. A compound or pharmaceutically acceptable salt as claimed in any one of claims 1 to 6, in which R^4 is hydrogen, methyl or ethyl.

8. A compound or pharmaceutically acceptable salt as claimed in any one of claims 1 to 7, in which R^5 is ethoxy or fluorinated ethoxy.

9. A compound or pharmaceutically acceptable salt as claimed in claim 8, in which R^5 is ethoxy, 2,2-difluoroethoxy or 2,2,2-trifluoroethoxy.

10. A compound or pharmaceutically acceptable salt as claimed in claim 9, in which R^5 is ethoxy.

11. A compound or pharmaceutically acceptable salt as claimed in any one of claims 1 to 10, in which R^6 is hydrogen.

12. A compound or pharmaceutically acceptable salt as claimed in any one of claims 1 to 11, in which R^9 is methyl or ethyl.

13. A compound or pharmaceutically acceptable salt as claimed in any one of claims 1 to 12, in which R^{10} is methyl or methoxy.

14. A compound or pharmaceutically acceptable salt as claimed in any one of claims 1 to 13, in which R^{11} is H.

15. A compound or pharmaceutically acceptable salt as claimed in any one of claims 1 to 14, in which R^7 and R^8 are not simultaneously CN.

16. A compound or pharmaceutically acceptable salt as claimed in any one of claims 1 to 15, in which R^7 is CN and R^8 is H or F.

17. A compound or pharmaceutically acceptable salt as claimed in any one of claims 1 to 15, in which R^7 is I and R^8 is H or F.

18. A compound or pharmaceutically acceptable salt as claimed in any one of claims 1 to 15, in which R^7 is Cl and R^8 is H or F.

19. A compound or pharmaceutically acceptable salt as claimed in any one of claims 1 to 18, in which a is 0.

20. A compound or pharmaceutically acceptable salt as claimed in any of claims 1 to 19, in which X^1 is -O-C(=O)-, -NH-, -NH-CH_2- or -NH-C(=O)-.

21. A compound or pharmaceutically acceptable salt as claimed in claim 20, in which X^1 is -NH-CH_2-.

22. A compound or pharmaceutically acceptable salt as claimed in any one of claims 1 to 21, in which X^2 is a single bond.

23. A compound or pharmaceutically acceptable salt as claimed in any one of claims 1 to 22, in which X^3 is N, and m and n are both 2.

24. A compound or pharmaceutically acceptable salt as claimed in any one of claims 1 to 22, in which X^3 is CH, and m and n are both 2, or are both 1, or m is 1 and n is 2.

25. A compound or pharmaceutically acceptable salt as claimed in any one of claims 1 to 24, in which X^4 is N.

26. A compound or pharmaceutically acceptable salt as claimed in any one of claims 1 to 25, in which A is phenylene.

27. A compound or pharmaceutically acceptable salt as claimed in claim 26, in which A is 1,4- or 1,3-phenylene.

28. A compound or pharmaceutically acceptable salt as claimed in any one of claims 1 to 25, in which A is pyridylene or pyrimidylene.

29. A compound or pharmaceutically acceptable salt as claimed in claim 28, in which A is 3,5- or 3,6-pyridylene.

30. A compound or pharmaceutically acceptable salt as claimed in any one of claims 1 to 16, in which

R^1 is H or methoxy;
R^2 is H;
R^3 is methoxy;
R^4 is H, methyl or ethyl;
R^5 is ethoxy;
R^6 is H;
R^7 is CN;
R^8 is H or F;
X^1 is -NH- or -$NHCH_2$-;
X^2 is a single bond;
X^3 is N;
X^4 is N;
A is 1,4-phenylene;
a is 0; and
m and n are 2.

31. A compound or pharmaceutically acceptable salt as claimed in claim 30, in which

R^1 is H or methoxy;
R^2 is H;
R^3 is methoxy;
R^4 is H or methyl;
R^5 is ethoxy;
R^6 is H;
R^7 is CN;
R^8 is H or F;
X^1 is -$NHCH_2$-;
X^2 is a single bond;

X^3 is N;
X^4 is N;
A is 1,4-phenylene;
a is 0, and
m and n are 2.

32. A compound that is:
1-(2,4-Dimethoxyphenylsulfonyl)-3-(2-ethoxypyridin-3-yl)-5-iodo-2-oxo-2,3-dihydro-1H-indol-3-yl 4-(4-methylpiperazin-1-yl)benzoate;
5-Cyano-3-(2-ethoxypyridin-3-yl)-1-(4-methoxyphenylsulfonyl)-2-oxo-2,3-dihydro-1H-indol-3-yl 4-(4-methylpiperazin-1-yl)benzoate;
5-Cyano-1-(2,4-dimethoxyphenylsulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxo-2,3-dihydro-1H-indol-3-yl 4-(4-methylpiperazin-1-yl)benzoate;
N-[5-Cyano-3-(2-ethoxypyridin-3-yl)-1-(4-methoxyphenylsulfonyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(4-methylpiperazin-1-yl)benzamid;
N-[5-Cyano-3-(2-ethoxypyridin-3-yl)-1-(4-methoxyphenylsulfonyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(4-ethylpiperazin-1-yl)benzamide;
N-[5-Cyano-1-(2,4-dimethoxyphenylsulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(4-methylpiperazin-1-yl)benzamide;
N-[5-Cyano-1-(2,4-dimethoxyphenylsulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(4-ethylpiperazin-1-yl)benzamide;
N-[1-[4-(2,2-Difluoroethoxy)phenylsulfonyl]-3-(2-ethoxypyridin-3-yl)-5-iodo-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(4-methylpiperazin-1-yl)benzamide;
1-(2,4-Dimethoxyphenylsulfonyl)-3-(2-ethoxypyridin-3-yl)-5-iodo-3-[4-(4-methylpiperazin-1-yl)benzylamino]-1,3-dihydroindol-2-one;
1-(2,4-Dimethoxyphenylsulfonyl)-3-(2-ethoxypyridin-3-yl)-5-iodo-3-(4-piperazin-1-yl-benzylamino)-1,3-dihydroindol-2-one as acetic acid salt;
5-Chloro-3-(2-ethoxypyridin-3-yl)-1-(4-methoxyphenylsulfonyl)-3-[4-(4-methylpiperazin-1-yl)-benzylamino]-1,3-dihydroindol-2-one;
5-Chloro-3-(2-ethoxypyridin-3-yl)-6-fluoro-1-(4-methoxyphenylsulfonyl)-3-[4-(4-methyl-piperazin-1-yl)benzylamino]-1,3-dihydroindol-2-one;
6-Chloro-3-(2-ethoxypyridin-3-yl)-5-fluoro-1-(4-methoxyphenylsulfonyl)-3-[4-(4-methyl-piperazin-1-yl)benzylamino]-1,3-dihydroindol-2-one;
5,6-Difluoro-3-(2-ethoxypyridin-3-yl)-1-(4-methoxyphenylsulfonyl)-3-[4-(4-methyl-piperazin-1-yl)benzylamino]-1,3-dihydroindol-2-one;
3-(2-Ethoxypyridin-3-yl)-5-fluoro-1-(4-methoxyphenylsulfonyl)-3-[4-(4-methylpiperazin-1-yl)benzylamino]-1,3-dihydroindol-2-one;
3-(2-Ethoxypyridin-3-yl)-1-(4-methoxyphenylsulfonyl)-3-[4-(4-methylpiperazin-1-yl)-benzylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
1-(2,4-Dimethoxyphenylsulfonyl)-3-(2-ethoxypyridin-3-yl)-3-[4-(4-methylpiperazin-1-yl)-benzylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
3-(2-Ethoxypyridin-3-yl)-1-(4-methoxy-2-trifluoromethoxyphenylsulfonyl)-3-[4-(4-

methyl-piperazin-1-yl)benzylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
3-(2-Ethoxypyridin-3-yl)-3-[4-(4-methylpiperazin-1-yl)benzylamino]-2-oxo-1-(4-trifluoromethoxyphenylsulfonyl)-2,3-dihydro-1H-indole-5-carbonitrile;
3-(2-Ethoxypyridin-3-yl)-3-[4-(4-methylpiperazin-1-yl)benzylamino]-2-oxo-1-[4-(2,2,2-trifluoroethoxy)phenylsulfonyl]-2,3-dihydro-1H-indole-5-carbonitrile;
1-[4-(2,2-Difluoroethoxy)phenylsulfonyl]-3-(2-ethoxypyridin-3-yl)-3-[4-(4-methylpiperazin-1-yl)benzylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
3-(2-Ethoxypyridin-3-yl)-1-[4-(2-fluoroethoxy)phenylsulfonyl]-3-[4-(4-methylpiperazin-1-yl)-benzylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
1-(4-Difluoromethoxyphenylsulfonyl)-3-(2-ethoxypyridin-3-yl)-3-[4-(4-methylpiperazin-1-yl)benzylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
3-(2-Ethoxypyridin-3-yl)-1-(2-methoxyphenylsulfonyl)-3-[4-(4-methylpiperazin-1-yl)-benzylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
3-(2-Ethoxypyridin-3-yl)-1-(3-methoxyphenylsulfonyl)-3-[4-(4-methylpiperazin-1-yl)-benzylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
1-(4-Chlorophenylsulfonyl)-3-(2-ethoxypyridin-3-yl)-3-[4-(4-methylpiperazin-1-yl)-benzylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
1-Phenylsulfonyl-3-(2-ethoxypyridin-3-yl)-3-[4-(4-methylpiperazin-1-yl)benzylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
1-(4-Cyanophenylsulfonyl)-3-(2-ethoxypyridin-3-yl)-3-[4-(4-methylpiperazin-1-yl)-benzylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
1-(2,4-Dimethoxyphenylsulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxo-3-(4-piperazin-1-yl-benzylamino)-2,3-dihydro-1H-indole-5-carbonitrile;
3-(2-Ethoxypyridin-3-yl)-1-(4-methoxyphenylsulfonyl)-2-oxo-3-(4-piperazin-1-yl-benzylamino)-2,3-dihydro-1H-indole-5-carbonitrile;
(S)-3-(2-Ethoxypyridin-3-yl)-1-(4-methoxyphenylsulfonyl)-2-oxo-3-(4-piperazin-1-yl-benzylamino)-2,3-dihydro-1H-indole-5-carbonitrile;
3-(2-Ethoxypyridin-3-yl)-3-[4-(4-ethylpiperazin-1-yl)benzylamino]-1-(4-methoxy-phenylsulfonyl)-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
1-(2,4-Dimethoxyphenylsulfonyl)-3-(2-ethoxypyridin-3-yl)-3-[4-(4-ethylpiperazin-1-yl)-benzylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
3-(2-Ethoxypyridin-3-yl)-6-fluoro-1-(4-methoxyphenylsulfonyl)-3-[4-(4-methylpiperazin-1-yl)benzylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
3-(2-Ethoxypyridin-3-yl)-6-fluoro-1-(4-methoxyphenylsulfonyl)-2-oxo-3-(4-piperazin-1-yl-benzylamino)-2,3-dihydro-1H-indole-5-carbonitrile;
3-(2-Ethoxypyridin-3-yl)-3-[4-(4-ethylpiperazin-1-yl)benzylamino]-6-fluoro-1-(4-methoxy-phenylsulfonyl)-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
1-[4-(2,2-Difluoroethoxy)phenylsulfonyl]-3-(2-ethoxypyridin-3-yl)-6-fluoro-3-[4-(4-methyl-piperazin-1-yl)benzylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
3-(2-Ethoxyphenyl)-1-(4-methoxyphenylsulfonyl)-3-[4-(4-methylpiperazin-1-yl)-benzylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
1-(2,4-Dimethoxyphenylsulfonyl)-3-(2-ethoxypyridin-3-yl)-5-iodo-3-[3-(4-

methylpiperazin-1-yl)benzylamino]-1,3-dihydroindol-2-one;
3-(2-Ethoxypyridin-3-yl)-5-iodo-1-(4-methoxy-2-trifluoromethoxyphenylsulfonyl)-3-[3-(4-methylpiperazin-1-yl)benzylamino]-1,3-dihydroindol-2-one;
3-(2-Ethoxypyridin-3-yl)-5-iodo-1-(4-methoxyphenylsulfonyl)-3-[3-(4-methylpiperazin-1-yl)-benzylamino]-1,3-dihydroindol-2-one;
3-(2-Ethoxypyridin-3-yl)-5-iodo-1-(2-methoxyphenylsulfonyl)-3-[3-(4-methylpiperazin-1-yl)-benzylamino]-1,3-dihydroindol-2-one;
1-(2,4-Dimethoxyphenylsulfonyl)-3-(2-ethoxypyridin-3-yl)-3-[3-(4-methylpiperazin-1-yl)-benzylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
3-(2-Ethoxypyridin-3-yl)-1-(4-methoxyphenylsulfonyl)-3-[3-(4-methylpiperazin-1-yl)-benzylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
3-(2-Ethoxypyridin-3-yl)-1-(2-methoxyphenylsulfonyl)-3-[3-(4-methylpiperazin-1-yl)-benzylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
1-(2,4-Dimethoxyphenylsulfonyl)-3-(2-ethoxypyridin-3-yl)-3-[2-(4-methylpiperazin-1-yl)-benzylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
3-(2-Ethoxypyridin-3-yl)-1-(4-methoxyphenylsulfonyl)-3-[2-(4-methylpiperazin-1-yl)-benzylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
3-(2-Ethoxypyridin-3-yl)-1-(2-methoxyphenylsulfonyl)-3-[2-(4-methylpiperazin-1-yl)-benzylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
1-(2,4-Dimethoxyphenylsulfonyl)-3-(2-ethoxypyridin-3-yl)-3-[4-(4-ethylpiperazin-1-yl)-phenylamino]-5-iodo-1,3-dihydroindol-2-one;
1-(2,4-Dimethoxyphenylsulfonyl)-3-(2-ethoxypyridin-3-yl)-5-iodo-3-[4-(4-methylpiperazin-1-yl)phenylamino]-1,3-dihydroindol-2-one;
3-(2-Ethoxypyridin-3-yl)-5-iodo-1-(4-methoxyphenylsulfonyl)-3-[4-(4-methylpiperazin-1-yl)-phenylamino]-1,3-dihydroindol-2-one;
5-Chloro-3-(2-ethoxypyridin-3-yl)-1-(4-methoxyphenylsulfonyl)-3-[4-(4-methylpiperazin-1-yl)phenylamino]-1,3-dihydroindol-2-one;
5-Chloro-3-(2-ethoxypyridin-3-yl)-6-fluoro-1-(4-methoxyphenylsulfonyl)-3-[4-(4-methyl-piperazin-1-yl)phenylamino]-1,3-dihydroindol-2-one;
6-Chloro-3-(2-ethoxypyridin-3-yl)-5-fluoro-1-(4-methoxyphenylsulfonyl)-3-[4-(4-methyl-piperazin-1-yl)phenylamino]-1,3-dihydroindol-2-one;
3-(2-Ethoxypyridin-3-yl)-5,6-difluoro-1-(4-methoxyphenylsulfonyl)-3-[4-(4-methylpiperazin-1-yl)phenylamino]-1,3-dihydroindol-2-one;
1-(2,4-Dimethoxyphenylsulfonyl)-3-(2-ethoxypyridin-3-yl)-3-[4-(4-methylpiperazin-1-yl)-phenylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
1-(2,4-Dimethoxyphenylsulfonyl)-3-(2-ethoxypyridin-3-yl)-3-[4-(4-ethylpiperazin-1-yl)-phenylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
3-(2-Ethoxypyridin-3-yl)-3-[4-(4-ethylpiperazin-1-yl)phenylamino]-1-(4-methoxy-phenylsulfonyl)-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
3-(2-Ethoxypyridin-3-yl)-3-[4-(4-ethylpiperazin-1-yl)phenylamino]-1-(2-methoxy-phenylsulfonyl)-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
3-(2-Ethoxypyridin-3-yl)-6-fluoro-1-(4-methoxyphenylsulfonyl)-3-[4-(4-

methylpiperazin-1-yl)phenylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
1-(2,4-Dimethoxyphenylsulfonyl)-3-(2-ethoxypyridin-3-yl)-5-iodo-3-[3-(4-methylpiperazin-1-yl)phenylamino]-1,3-dihydroindol-2-one;
3-(2-Ethoxypyridin-3-yl)-1-(4-methoxyphenylsulfonyl)-3-[3-(4-methylpiperazin-1-yl)-phenylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
1-(2,4-Dimethoxyphenylsulfonyl)-3-(2-ethoxypyridin-3-yl)-3-[3-(4-methylpiperazin-1-yl)-phenylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
3-(4-Azetidin-3-ylphenylamino)-1-(2,4-dimethoxyphenylsulfonyl)-3-(2-ethoxypyridin-3-yl)-5-iodo-1,3-dihydroindol-2-one;
1-(2,4-Dimethoxyphenylsulfonyl)-3-(2-ethoxypyridin-3-yl)-3-[4-(1-ethylazetidin-3-yl)-phenylamino]-5-iodo-1,3-dihydroindol-2-one;
3-(4-Azetidin-3-ylphenylamino)-3-(2-ethoxypyridin-3-yl)-5-iodo-1-(4-methoxy-phenylsulfonyl)-1,3-dihydroindol-2-one;
3-(2-Ethoxypyridin-3-yl)-3-[4-(1-ethylazetidin-3-yl)phenylamino]-5-iodo-1-(4-methoxy-phenylsulfonyl)-1,3-dihydroindol-2-one;
1-(2,4-Dimethoxyphenylsulfonyl)-3-(2-ethoxypyridin-3-yl)-5-iodo-3-[6-(4-methylpiperazin-1-yl)pyridin-3-ylamino]-1,3-dihydroindol-2-one;
3-(2-Ethoxypyridin-3-yl)-5-iodo-1-(4-methoxyphenylsulfonyl)-3-[6-(4-methylpiperazin-1-yl)-pyridin-3-ylamino]-1,3-dihydroindol-2-one;
1-Phenylsulfonyl-3-(2-ethoxypyridin-3-yl)-5-iodo-3-[6-(4-methylpiperazin-1-yl)pyridin-3-ylamino]-1,3-dihydroindol-2-one;
3-(2-Ethoxypyridin-3-yl)-5-iodo-1-(4-methoxyphenylsulfonyl)-3-[4-(4-methylpiperazin-1-carbonyl)phenylamino]-1,3-dihydroindol-2-one;
1-(2,4-Dimethoxyphenylsulfonyl)-3-(2-ethoxypyridin-3-yl)-5-iodo-3-[4-(4-methylpiperazin-1-carbonyl)phenylamino]-1,3-dihydroindol-2-one;
3-(2-Ethoxypyridin-3-yl)-1-(4-methoxyphenylsulfonyl)-3-[4-(4-methylpiperazin-1-carbonyl)-phenylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
1-(2,4-Dimethoxyphenylsulfonyl)-3-(2-ethoxypyridin-3-yl)-3-[4-(4-methylpiperazin-1-carbonyl)phenylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
1-(2,4-Dimethoxyphenylsulfonyl)-3-(2-ethoxypyridin-3-yl)-3-[4-(4-methylpiperazin-1-ylmethyl)phenylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
3-(2-Ethoxypyridin-3-yl)-1-(4-methoxyphenylsulfonyl)-3-[4-(4-methylpiperazin-1-ylmethyl)-phenylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
3-(2-(2,2-Difluoroethoxy)pyridin-3-yl)-1-(4-methoxyphenylsulfonyl)-3-[4-(4-methyl-piperazin-1-yl)benzylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
1-(4-Methoxyphenylsulfonyl)-3-(2-(2,2,2-trifluoroethoxy)pyridin-3-yl)-3-[4-(4-methyl-piperazin-1-yl)benzylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
3-(2-(2,2-Difluoroethoxy)phenyl)-1-(4-methoxyphenylsulfonyl)-3-[4-(4-methylpiperazin-1-yl)-benzylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
3-[4-(4-Ethylpiperazin-1-yl)phenylamino]-1-(4-methoxyphenylsulfonyl)-3-(2-(2,2-difluoroethoxy)pyridin-3-yl)-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
3-[4-(4-Ethylpiperazin-1-yl)phenylamino]-1-(4-methoxyphenylsulfonyl)-3-(2-(2,2,2-


trifluoroethoxy)pyridin-3-yl)-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
3-(2-(2,2-Difluoroethoxy)phenyl)-3-[4-(4-ethylpiperazin-1-yl)phenylamino]-1-(4-methoxy-phenylsulfonyl)-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
1-(2,4-Dimethoxyphenylsulfonyl)-3-[4-(4-methylpiperazin-1-yl)phenylamino]-3-(2-(trifluoromethoxy)phenyl)-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
1-(2,4-Dimethoxyphenylsulfonyl)-3-[4-(4-methylpiperazin-1-yl)phenylamino]-3-(2-(trifluoromethoxy)phenyl)-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;

or a pharmaceutically acceptable salt thereof.

33. A compound that is
3-(2-Ethoxypyridin-3-yl)-1-(4-methoxyphenylsulfonyl)-3-[4-(4-methylpiperazin-1-yl)-benzylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
3-(2-Ethoxypyridin-3-yl)-1-(4-methoxyphenylsulfonyl)-2-oxo-3-(4-piperazin-1-yl-benzylamino)-2,3-dihydro-1H-indole-5-carbonitrile;
(S)-3-(2-Ethoxypyridin-3-yl)-1-(4-methoxyphenylsulfonyl)-2-oxo-3-(4-piperazin-1-yl-benzylamino)-2,3-dihydro-1H-indole-5-carbonitrile;
3-(2-Ethoxypyridin-3-yl)-3-[4-(4-ethylpiperazin-1-yl)benzylamino]-1-(4-methoxy-phenylsulfonyl)-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
3-(2-Ethoxypyridin-3-yl)-6-fluoro-1-(4-methoxyphenylsulfonyl)-3-[4-(4-methylpiperazin-1-yl)benzylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
1-(2,4-Dimethoxyphenylsulfonyl)-3-(2-ethoxypyridin-3-yl)-3-[4-(4-methylpiperazin-1-ylmethyl)phenylamino]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;

or a pharmaceutically acceptable salt thereof.

34. A compound of the formula XVIII



(XVIII)

in which R^1, R^2, R^3, R^5, R^6, R^7, R^8, X^1, X^4 and A are as defined in any one of claims 1 to 31, and

R^{12} is halogen, CN, OR^a or NR^bR^c, in which

R^a is H, C_1-C_4-alkyl, phenyl or benzyl; and

R^b and R^c are independently of one another H, C_1-C_4-alkyl, C_1-C_4-alkoxy, phenyl or benzyl.

35. A compound as claimed in claim 34, in which R^{12} is halogen.

36. A pharmaceutical composition comprising at least one compound as defined in any one of claims 1 to 33 and/or at least one pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable carrier.

37. The use of a compound as defined in any one of claims 1 to 33 or of pharmaceutically acceptable salts thereof for the manufacture of a medicament for the treatment and/or prophylaxis of vasopressin-dependent diseases.

38. The use of a compound as defined in any one of claims 1 to 33 or of pharmaceutically acceptable salts thereof for the manufacture of a medicament for the treatment and/or prophylaxis of diseases selected from diabetes, insulin resistance, nocturnal enuresis, incontinence, diseases in which impairments of blood clotting occur, hypertension, pulmonary hypertension, heart failure, myocardial infarction, coronary spasm, unstable angina, PTCA (percutaneous transluminal coronary angioplasty), ischemias of the heart, impairments of the renal system, edemas,

renal vasospasm, necrosis of the renal cortex, hyponatremia, hypokalemia, Schwartz-Bartter syndrome, impairments of the gastrointestinal tract, gastritic vasospasm, hepatocirrhosis, gastric and intestinal ulcers, emesis, emesis occurring during chemotherapy, travel sickness,
affective disorders,
anxiety disorders, stress-dependent anxiety disorders,
memory impairments, Alzheimer's disease,
psychoses, psychotic disorders;
Cushing's syndrome and other stress-dependent diseases,
sleep disorders,
depressive disorders,
vasomotor symptoms, thermoregulatory dysfunctions,
drug or pharmaceutical dependencies; stress caused by withdrawal of one or more factors mediating the dependence; stress-induced relapses into drug or pharmaceutical dependencies,
schizophrenia and psychosis;

and/or for delaying micturition.

39. The use as claimed in claim 38 for the treatment and/or prophylaxis of childhood onset mood disorders.